Nonnenmacher B, Kruger Kjaer S, Svare E I, Scott J D, Hubbert N L, van den Brule A J, Kirnbauer R, Walboomers J M, Lowy D R, Schiller J T
NIH, Bethesda, MD 20892, USA.
Int J Cancer. 1996 Dec 11;68(6):704-9. doi: 10.1002/(SICI)1097-0215(19961211)68:6<704::AID-IJC3>3.0.CO;2-7.
Sexually transmitted genital human papillomavirus (HPV) infection, most often HPV 16, is considered the major etiologic determinant of cervical cancer. However, some studies have found relatively low prevalences of genital tract HPV DNA in some geographical areas, such as Greenland, that have high rates of cervical cancer. We sought to evaluate HPV 16 infection in high-risk cohorts using a serologic assay that assesses prior exposure as well as current infection and to compare the results with those obtained using a sensitive PCR-based HPV DNA assay. An ELISA based on HPV 16 virus-like particles was used to detect IgG serum antibodies in women attending sexually transmitted disease (STD) clinics in Nuuk, Greenland and Copenhagen, Denmark. Using a preassigned cut-off, 56% of Greenlandic and 41% of Danish women were seropositive (p = 0.02). In Greenlandic women, there was a non-significant increase in seropositivity with age, and odds ratios for seropositivity were similar for women with more than 5 lifetime sex partners. Seropositivity in the Danish women, however, increased linearly with increases in these 2 factors, which are likely correlates of lifetime exposure to genital HPVs. In contrast, any genital HPV DNA (HPV16 specifically) was detected in 24% and 36% of Greenlandic and Danish women, respectively and was most frequently detected in women below 20. The finding that HPV DNA prevalences, unlike seroprevalences, tended to decrease with increased lifetime risk of infection, provides an explanation for the lack of correlation between HPV DNA prevalences and cervical cancer risk in previous studies of high-risk populations.
性传播的生殖器人乳头瘤病毒（HPV）感染，最常见的是HPV 16型，被认为是宫颈癌的主要病因。然而，一些研究发现，在某些宫颈癌发病率较高的地理区域，如格陵兰岛，生殖道HPV DNA的患病率相对较低。我们试图使用一种血清学检测方法评估高危人群中的HPV 16感染情况，该方法可评估既往暴露以及当前感染情况，并将结果与使用基于PCR的敏感HPV DNA检测方法获得的结果进行比较。基于HPV 16病毒样颗粒的酶联免疫吸附测定（ELISA）用于检测在格陵兰努克和丹麦哥本哈根的性传播疾病（STD）诊所就诊的女性血清中的IgG抗体。使用预先设定的临界值，56%的格陵兰女性和41%的丹麦女性血清呈阳性（p = 0.02）。在格陵兰女性中，血清阳性率随年龄增长有不显著的增加，对于有超过5个性伴侣的女性，血清阳性的优势比相似。然而，丹麦女性的血清阳性率随这两个因素的增加呈线性增加这两个因素可能与一生暴露于生殖器HPV相关。相比之下，分别在24%的格陵兰女性和36%的丹麦女性中检测到任何生殖器HPV DNA（特别是HPV16），且最常在20岁以下的女性中检测到。与血清阳性率不同，HPV DNA患病率往往随着一生感染风险的增加而降低，这一发现为先前高危人群研究中HPV DNA患病率与宫颈癌风险缺乏相关性提供了解释。
